Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Lockdown leads to double unplanned pregnancies
Fri October 22nd - Unplanned pregnancies almost doubled during the first lockdown in the UK, a major study reports today. More
Promising development in treatment for glioblastoma multiforme
Fri October 22nd - A major advance in brain tumour research could pave the way for personalised treatment for the most deadly form of the disease, British scientists say. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

'Game changing' technology promising for cardiac patients

Thursday October 7th 2021

Implantable heart technology could be “game-changing” for monitoring cardiac patients, especially when they are at high risk of dying, a study has found.

Research led by the University of Manchester and Manchester University NHS Foundation Trust used implantable pacemakers and defibrillators that contain multiple sensors, which enables a patient’s heart to be continuously monitored 24 hours a day.

The study, published in Europace, involved examining data from 439 patients who were being cared for at Manchester Royal Infirmary (MRI) over two years.

The researchers found a three-fold increase in the odds of mortality for patients who spent at least one day in “high-risk” status and a 26% increase in the odds of mortality for patients who had 14 consecutive days or more in a high-risk status, compared with those whose high-risk episodes were shorter.

They are now investigating if integration of the remotely monitored device data into healthcare pathways can reduce hospitalisations and mortality.

Dr Fozia Ahmed, honorary reader in cardiovascular sciences from The University of Manchester and consultant cardiologist at The Manchester Heart Centre, part of the MRI, said: “Remote monitoring capabilities of modern-day cardiac devices enables continuous monitoring of health-related data in the patients’ own homes.

“The data can help identify when there is a potentially significant shift in a patient’s clinical condition, helping to predict future adverse clinical events, such as hospitalisation and death.

“Historically, cardiologists have seen patients at six to 12-month hospital-based appointments. If a patient with heart failure is unwell between appointments, then we rely on the patient getting in touch. But patients don’t always know they are unwell until it is too late.”

“We believe this technology could be a game-changer in the management of cardiac patients, particularly those with heart failure.”

He added that the device-derived alerts are being used, which notify the care team when a patient is detected by the device as ‘high-risk’, prompting a telephone consultation with a specialist.

Lead statistician for the study Dr Camilla Sammut-Powell, from the NIHR Applied Research Collaboration Greater Manchester at The University of Manchester, said: “This is the first prospective study to show that remotely monitored cardiovascular implantable electronic device (CIED) data, summarised as a risk score, can be used to predict mortality.

“This routinely monitored data, automatically collected every day, can help discriminate between patients at high and low risk of death.

“Such information may personalise a clinician’s decision making towards ensuring that the patient is in receipt of therapies designed to improve their long-term prognosis.”

The researchers are undertaking a follow-on study to evaluate the costs and resources of implementing the new heart failure care pathway.

Ahmed FZ, Sammut-Powell C, Shing Kwok C et al. Remote monitoring data from cardiac implantable electronic devices predicts all-cause mortality. Europace 3 October 2021.


Tags: Heart Health | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)